Pilot Study of Apremilast (CC-10004) in the Treatment of Moderate to Severe Lichen Planus
Status:
Unknown status
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study is designed to demonstrate to efficacy and safety of Apremilast 20mg oral
administration twice daily over 12 weeks in subjects with moderate to severe lichen planus.
The hypothesis is that the subjects will achieve a significant clinical improvement in their
skin disease according to a specialized physician grading scale.